Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...
Roche Holding AG licensed a new weight-loss drug from Zealand Pharma A/S for as much as $5.3 billion, bolstering the Swiss ...
Viking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its ...
Zealand Pharma shares rose sharply after the Danish pharmaceutical company struck a licensing and collaboration deal of up to $5.3 billion with Roche. Shares in Zealand were up 25% at 609 Danish ...
Roche Holding AG hired a senior executive from rival Novo Nordisk A/S as the Swiss drugmaker prepares to enter the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback